Multiple Faces of Therapeutic Inertia in Diabetes
Sunday, June 23, at 4:30 p.m. ET
Room W311
Orange County Convention Center
Therapeutic Inertia in Treatment of Diabetes—Are We Making Progress?
Steven Edelman, MD
Founder and Director,
Taking Control of Your Diabetes 501c3
What is your presentation about?
Clinical inertia refers to the failure to initiate or intensify therapy when indicated, particularly in the context of managing chronic diseases like diabetes. Clinical inertia still remains an obstacle in achieving glycemic and other health goals for people with type 1 and type 2 diabetes. Clinical inertia is contributed to by patient-, provider-, and system-level problems. I will briefly discuss these issues and give a report card on how we are doing in the ULS over time.
How do you hope your presentation will impact diabetes research or care?
I hope my presentation opens the eyes of clinicians and other stakeholders regarding how badly clinical inertia is affecting the health and well-being of the people living with diabetes and their loved ones—and leads to positive changes.
How did you become involved with this area of diabetes research or care?
Living with type 1 diabetes since 1970 and being intimately involved with teaching and patient care, I have seen the adverse effects of clinical inertia in almost every health care system. The effects are devastating in terms of complications and a tremendous drain on our limited health care dollar.